MedTrace Logo

Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia

NCT03992937 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2020-12-02

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of the vaginal micronized progesterone and Levonorgestrel-releasing Intrauterine System for treatment of non-atypical endometrial hyperplasia in premenopausal women.

Conditions

  • Endometrial Hyperplasia Without Atypia

Interventions

DRUG

Vaginal Micronized Progesterone

Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.

DEVICE

Levonorgestrel-Intrauterine System

Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.

Sponsors & Collaborators

  • Kocaeli University

    lead OTHER

Principal Investigators

  • Şener Gezer, M.D · Kocaeli University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-20
Primary Completion
2020-12-01
Completion
2020-12-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03992937 on ClinicalTrials.gov